NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

Abstract Background NTP42 is a novel antagonist of the thromboxane prostanoid receptor (TP), currently in development for the treatment of pulmonary arterial hypertension (PAH). PAH is a devastating disease with multiple pathophysiological hallmarks including excessive pulmonary vasoconstriction, va...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Eamon P. Mulvaney, Helen M. Reid, Lucia Bialesova, Annie Bouchard, Dany Salvail, B. Therese Kinsella
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2020-04-01
coleção:	BMC Pulmonary Medicine
Assuntos:	Thromboxane Prostanoid Thromboxane receptor antagonist Pulmonary arterial hypertension PAH Monocrotaline
Acesso em linha:	http://link.springer.com/article/10.1186/s12890-020-1113-2
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!